Samsung Biologics will acquire all of its shares in Samsung Bioepis held by its partner Biogen. Stock purchase funds are raised through a paid-in capital increase in shareholder allocation. Samsung BioLogics announced on the 28th that it has decided to acquire all 10,341,852 shares of Samsung Bioepis held by Biogen in the U.S. for $2.3 billion (about 2.7655 trillion won). Of the $2.3 billion cost of purchasing a stake in Samsung Bioepis, the acquisition price will be paid in installments over the next two years, excluding $50 million in "earn-out" costs, which will be additionally paid if certain conditions are met after the contract is signed. The contract will take effect from the time the first payment of $1 billio